Probiotics in the Treatment of Inflammatory Bowel Disease
While considerable progress has been made in the treatment of inflammatory bowel diseases (IBD), alternative options are constantly sought by adult patients as well as frustrated parents of young patients. These include dietary modifications, food supplements, and, more recently, probiotics.
Their potential use is based on the demonstrated role of the altered mucosal immune response to bacterial agents that eventually leads to the chronic intestinal inflammation that characterized IBD. In fact, probiotics might conceivably be beneficial due to multiple mechanisms: stimulation of anti-inflammatory cytokines, inhibition of inflammatory cytokines, strengthening of intestinal barrier, and antagonistic action on pathogens. Such mechanisms have been largely extensively investigated in animal models both in vitro and in vivo.
Despite such premise, a relatively scarce number of clinical trials are available, and of them only a handful in pediatric age. Overall, available evidence is very disappointing in the treatment of Crohn’s disease (CD), where no recommendation for probiotic use can be made. In ulcerative colitis (UC), on the other hand, there is clinical evidence of efficacy for some specific strains and especially for multi-strain preparations.
In summary, more data are needed very likely to yield a better understanding on what strains and in what doses should be used in different specific clinical settings.
KeywordsCrohn’s disease IBD Inflammatory bowel disease Lactobacillus Probiotics Ulcerative colitis De Simone Formulation
- Abraham BP, Quigley EMM (2017) Probiotics in inflammatory bowel disease. Gastroenterol Clin N Am 46:769–782Google Scholar
- Alard J, Peucelle V, Boutillier D, Breton J, Kuylle S, Pot B, Holowacz S, Grangette C (2018) New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches. Benef Microb 9:317–331Google Scholar
- Basson AR, Lam M, Cominelli F (2017) Complementary and alternative medicine strategies for therapeutic gut microbiota modulation in inflammatory bowel disease and their next-generation approaches. Gastroenterol Clin N Am 46:689–729Google Scholar
- Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL (2005) A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839PubMedGoogle Scholar
- Chassaing B, Darfeuille-Michaud A (2011) The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:1720–1728Google Scholar
- Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A (2002) Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66:246–256Google Scholar
- Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A (2009) Effect of a probiotic preparation (De Simone Formulation) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104:437–443Google Scholar
- Miele E, Shamir R, Aloi M, Assa A, Braegger C, Bronsky J, De Ridder L, Escher JC, Hojsak I, Kolacek S, Koletzko S, Levine A, Lionetti P, Martinelli M, Ruemmele F, Russell RK, Boneh RS, Van Limbergen J, Veereman G, Staiano A (2018) Nutrition in pediatric inflammatory bowel disease: a position paper on behalf of the porto inflammatory bowel disease group of the European Society of pediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr 66:687–708PubMedGoogle Scholar
- Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L (2012) Randomised clinical trial: the effectiveness of lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 35:327–334PubMedPubMedCentralGoogle Scholar
- Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA (2014) Ciprofloxacin and probiotic Escherichia coli nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 8:1498–1505PubMedGoogle Scholar
- Rodriguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, Fernandez-Caballero JA, Garcia F, Rodriguez-Cabezas ME, Galvez J (2018) The administration of Escherichia coli nissle 1917 ameliorates development of DSS-induced colitis in mice. Front Pharmacol 9:468PubMedPubMedCentralGoogle Scholar
- Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A (2016) Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World J Gastroenterol 22:5505–5511PubMedPubMedCentralGoogle Scholar
- Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS (2015) Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev:CD001176. https://doi.org/10.1002/14651858.CD001176.pub3
- Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54Google Scholar